Valencia

• Phase 3 study of pembrolizumab plus lenvatinib in endometrial carcinoma Ended
  2023-505614-17-00 5 2019-09-20 Participants with advanced or recurrent endometrial carcinoma
• A study to learn about the effects and safety of obeticholic acid in combination with bezafibrate in participants with primary biliary chola … Ended
  2024-513762-18-00 4 2019-09-20 Primary Biliary Cholangitis (PBC)
• Nivo versus Nivo/Ipi or versus other chemotherapies to treat colorectal cancer Ended
  2023-503956-29-00 5 2019-08-26 Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient M
• Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended
  2022-500785-10-00 5 2019-08-23 Metastatic Castration-Resistant Prostate Cancer
• Open-label Follow-up Study of Soticlestat in Adults and Children with Developmental Epileptic Encephalopathies Ended
  2022-502801-13-00 4 2019-07-26 Epileptic Encephalopathies: Dravet Syndrome, Lennox Gastaut Syndrome,
• Pembrolizumab with Lenvatinib versus Docetaxel for Metastatic NSCLC after Platinum Doublet Chemotherapy and Immunotherapy Ended
  2022-501439-18-00 5 2019-06-26 NSCLC with squamous or nonsquamous histology
• Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLC Ended
  2023-509774-40-00 5 2019-06-25 Stage IV lung cancer condition
• A study to assess different investigational drugs for the treatment if hidradenitis suppurativa Ended
  2023-509296-16-00 4 2019-06-17 Moderate to severe hidradenitis suppurativa
• A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eli … Ended
  2022-501970-20-01 5 2019-06-07 Cis-eligible Muscle-invasive bladder cancer.
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok
• A phase 1 study of oral Debio 0123 in combination with carboplatin in patients with advanced solid tumors Ended
  2024-510984-52-00 1 2019-05-24 Patients with tumors
• A study evaluating the efficacy and safety of ralinepag in treatment of patients with pulmonary arterial hypertension. Ended
  2023-509304-16-00 5 2019-05-16 Pulmonary arterial hypertension (PAH)
• Study of chemotherapy and immunotherapy for patients with lung cancer bounded in the thorax and potentially resectable Ended
  2024-513731-24-00 4 2019-05-14 Non-small cell lung cancer (NSCLC)
• HELIOS-A: A Phase 3 Global Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis Ended
  2023-508365-33-00 5 2019-04-09 Hereditary Transthyretin Amyloidosis
• A clinical study to test the safety (any good or bad effects) of CC-90011 in combination with standard of care (cisplatin and etoposide), on … Ended
  2023-509800-14-00 3 2019-02-25 extensive stage small cell lung cancer
• A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML Ended
  2023-508655-39-00 7 2019-02-13 Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia(CMML)
• A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Su … Ended
  2023-506687-13-00 5 2019-01-31 Primary Generalized Tonic-Clonic Seizures
• Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema) – Measure Up 2 Ended
  2022-502936-38-00 5 2019-01-09 Moderate and Severe Atopic Dermatitis
• A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabin … Ended
  2024-513513-12-00 5 2019-01-06 Cholangiocarcinoma
• First-line chemotherapy plus pembrolizumab and olaparib for BRCA nonmutated advanced EOC Ended
  2022-502124-52-00 5 2018-12-18 Advanced epithelial ovarian cancer
• Combination of Talimogene Laherparepvec (modified Herpes Virus) with atezolizumab (monoclonal antibody) in patients with residual breast can … Ended
  2023-508550-25-00 3 2018-12-10 Pre and post-menopausal women with resectable primary breast cancer an
• Study of efficacy and safety of asciminib in addition to imatinib in CML-CP patients without a deep level or response on imatinib Ended
  2024-515040-23-00 4 2018-11-26 Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously tre
• Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) Ended
  2023-505494-32-00 5 2018-10-15 Focal segmental glomerulosclerosis (FSGS)
• A study that allows patients from previous studies to continue on the medication. The aim of the study is to determine how safe and effectiv … Ended
  2023-508955-37-00 5 2018-10-10 Moderate to severe atopic dermatitis

Showing 1,777–1,800 of 1,853 trials